Chronix Biomedical to present clinical data on its cell-free DNA approach as an early predictor of response to chemotherapy at the AACR Annual Meeting
Howard B. Urnovitz, Ekkehard Schutz, et al. Changes in tumor cell-free DNA copy number instability (CNI) predict therapeutic response in metastatic cancers AACR, 19 April 2016
Tumor cell-free DNA (cfDNA) has the potential to provide minimally invasive patient specific biomarkers to monitor tumor burden. Gains and losses of chromosomal regions - as a hallmark of cancer - have been detected in plasma as copy number aberrations (CNAs), and for several cancers a relation to tumor size has been reported.